Clinical Trial Update: A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 open-label study of a GARFT inhibitor in patients with metastatic non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GARFT inhibitor

Snippet

Sponsor: Pfizer | Conditions: Lung Neoplasms | Phase 2 | Status: WITHDRAWN